Immediate Impact

24 standout
Sub-graph 1 of 11

Citing Papers

CAR T therapies in multiple myeloma: unleashing the future
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
2 intermediate papers

Works of Will Donnellan being referenced

PS945 KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3
2019
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
2018

Author Peers

Author Last Decade Papers Cites
Will Donnellan 37 45 15 18 5 71
R. Andrew Harkins 25 40 7 7 7 64
T.B. Johannesen 40 44 29 49 4 106
Ekaterina Chigrinova 16 27 10 16 5 60
Elen Oliveira 34 14 41 33 5 96
H Schouten 51 37 5 19 6 76
Sandra Le Guyader-Peyrou 38 54 16 8 5 74
Kerstin Busch 40 95 27 16 5 164
Sunkyu Kim 33 16 37 19 7 88
José Fernandes 45 19 14 30 5 85
R. Scott Mead 47 14 8 12 5 87

All Works

Loading papers...

Rankless by CCL
2026